Sanofi and Zealand Shares Drop

Sanofi and Zealand Shares Drop

Sources confirm that the U. S. setback for the diabetes drug has severely hit Sanofi and Zealand.

According to the statements released by the French Drugmaker Sanofi on Thursday, it has decided to presently withdraw its U. S. application for the diabetes treatment lixisenatide. The company officials said that they await the results of the ongoing cardiovascular patient study.

The company's above decision will delay the launch of the drug in the world's biggest market. As an immediate effect of its decision, the position of its shares in the market has fallen down by 1.6 percent. At 0720 GMT, the shares of Sanofi reported down along with a trembling position of its smaller Danish partner Zealand Pharma too, which dropped by 20 percent.

Sanofi look forward at resubmitting its application in 2015. It said that till then the cardiovascular test will be complete. The company's decision is not at all concerned with the safety issues or deficiencies in the new drug application, the officials explained.

Europe government has already approved the selling of Lixisenatide under the brand name Lyxumia. But, Sanofi awaits the full results of the evaluation of lixisenatide in acute coronary syndrome. The new drug will treat the patients with high cardiovascular risk.


FrenchTribune Specials

Coventry Amateur Astronomer wins Sir Patrick Moore Prize

Cameron Watson, 16, a young amateur astronomer from Coventry who is a sixth former at Kenilworth Castle College, won a prestigious award for his outstanding star-gazing talents.

He won the British Astronomical Association's most recently instituted award - The Sir Patrick Moore Prize. This particular prize was named after the astronomer...

Most Popular

PD-1 inhibitors Show Promise for Hodgkin’s lymphoma

A report released by researchers on 56th Annual Meeting...

China rejects proposal to set limits on Carbon Emissions

At a climate conference in Lima, Peru on Saturday China...

Gilead Sciences expecting blockbuster sales of hepatitis C drug Sovaldi

Stock price of biotechnology major Gilead Sciences...

Edmonton man arrested for speeding; tested positive for impaired driving

On Friday morning, a 43-year-old Edmonton man was taken...

Poll

Can Greece Come out of Economic Problems: